Delayed Ejaculation & Anejaculation
Inhibited Ejaculation - SSRI-Induced, Neurologic, Age-Related, and Idiopathic
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved drug for delayed ejaculation
Reference only. Not medical advice.
What can go wrong
The condition causes infertility, distress, and relationship strain. Off-label drug trials carry their own risks (cabergoline-associated valvulopathy at higher chronic doses, cyproheptadine sedation, amantadine effects) with uncertain benefit. Importantly, idiopathic acquired anejaculation/DE should prompt review for neurologic disease, diabetes, hypogonadism, and medication causes before being labeled psychogenic.
This is something to take to a clinician. The Atlas can tell you what is known about delayed ejaculation & anejaculation in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Delayed ejaculation (DE) is a marked, distressing delay in or inability to achieve ejaculation despite adequate stimulation and arousal; at the extreme it becomes anejaculation (no ejaculation at all). It is far less discussed than PE and notoriously difficult to manage because there is no approved drug and the causes are heterogeneous: SSRIs and other serotonergic/antiadrenergic drugs, diabetic and other neuropathies, spinal cord injury, pelvic surgery (including RPLND), hypogonadism, aging, and idiopathic/lifelong forms. Management is largely about removing reversible causes and trying off-label agents with weak evidence.
The hard-to-treat opposite of PE - and the one with the fewest options.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Ejaculation requires coordinated sympathetic emission (seminal emission into the posterior urethra) and somatic expulsion, with a serotonin/dopamine balance setting the threshold. DE reflects an excessively high threshold: too much serotonergic tone (SSRIs), too little dopaminergic/adrenergic drive, impaired sensory input or central processing, or interrupted autonomic wiring (neuropathy, surgery). Because the off switch is being held down by multiple possible mechanisms, no single drug reliably reverses it.
How it is taken
Management is mainly cause-directed: switch a high-DE-risk SSRI (e.g., paroxetine) to bupropion or a lower-risk agent or add bupropion; treat hypogonadism; optimize glycemic control. Off-label trials include cabergoline, cyproheptadine (taken before sex), and amantadine, all with limited evidence. Penile vibratory stimulation is first-line for retrieving sperm in many neurogenic anejaculation cases, with electroejaculation if that fails.
What people get wrong
Often saidLasting a very long time is always a good thing
ActuallyMarked delay or inability to ejaculate is itself a recognized dysfunction that causes distress, relationship strain, and infertility - it is not simply 'good stamina.'
Often saidThere is a pill for delayed ejaculation like there is for ED
ActuallyThere is no FDA-approved drug for DE; management focuses on removing reversible causes and trying off-label agents with weak evidence, which is part of why DE is hard to treat.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
DE is the mirror image of PE but far harder to treat: PE has multiple effective serotonergic and topical options, whereas DE has no approved drug and only weak off-label candidates. The most productive step is often subtractive - reducing or switching an offending SSRI, optimizing testosterone, controlling diabetes - rather than adding a drug. For neurogenic anejaculation, fertility (not orgasm) is addressed with vibratory stimulation, electroejaculation, or surgical sperm retrieval.
At a glance
- Most common reversible cause
- SSRI/SNRI antidepressants
- Neurologic causes
- Diabetic neuropathy, SCI, MS, pelvic surgery
- Hormonal/age
- Low testosterone, aging
- FDA drug for DE
- None
- Off-label tried
- Cabergoline, bupropion, cyproheptadine, oxytocin (weak data)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Delayed Ejaculation & Anejaculation. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Reviews of antidepressant sexual dysfunction2000s
SSRIs (paroxetine prominently) cause dose-related delayed/absent orgasm in a large minority of users - the same effect harnessed therapeutically in PE
Off-label pharmacotherapy reviews (cabergoline, bupropion, cyproheptadine, amantadine, oxytocin)various
Small, mostly uncontrolled studies; no agent has robust RCT support for DE
Penile vibratory stimulation / electroejaculation in neurogenic anejaculationestablished
Effective for sperm retrieval in SCI and other neurogenic anejaculation, enabling fertility